Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Emory University (Winship Cancer Institute)

Sites in Atlanta, GA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1470
Shown on this page
12
Current sort
Recently updated
Campus scope
Emory University (Winship Cancer Institute), Atlanta, GA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Emory University (Winship Cancer Institute), Atlanta, GA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 661–672 of 1,470 matching trials with a site at Emory University (Winship Cancer Institute), Atlanta, GA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

NCT05570253
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Metastatic Triple-Negative Breast Cancer
Interventions
Eribulin, SDX-7320, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Not applicable Interventional

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure
Interventions
BrioVAD System, HeartMate 3
Device
Lead sponsor
BrioHealth Solutions, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 1Phase 2 Interventional

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

NCT07147231
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Pidnarulex, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 2 Interventional

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931
Status at this site: Recruiting
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Corabotase, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Tucson, Arizona • Fountain Valley, California • Loma Linda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting Not applicable Interventional

TECTONIC CAD IVL IDE Study

NCT06885177
Site status not listed — check the official record
View directory record Official record
Conditions
Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Interventions
Experimental
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 3 Interventional

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities

NCT06399705
Status at this site: Recruiting
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting, Percutaneous coronary intervention
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 3 Interventional

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

NCT06713616
Status at this site: Recruiting
View directory record Official record
Conditions
Depression
Interventions
Racemic ketamine, Spravato (Esketamine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 1 Interventional

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT03666000
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 1 Interventional

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

NCT04585958
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
Site status not listed — check the official record
View directory record Official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The PREVENT Resilience Study

NCT07568145
Status at this site: Recruiting
View directory record Official record
Conditions
Psychological Trauma
Interventions
Transcranial Magnetic Stimulation (TMS), TMS Sham
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 3 Interventional

REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

NCT06399692
Status at this site: Recruiting
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 12:24 PM EST

About this Emory University (Winship Cancer Institute) institution page

What this page lists
ClinicalTrials.gov records that list Emory University (Winship Cancer Institute) in Atlanta, GA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.